Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study

We present data from the TRuE-V1/TRuE-V2 rollover TRuE-V long-term extension study evaluating withdrawal and continuation of ruxolitinib cream treatment. Among patients with near-complete facial repigmentation in TRuE-V1/TRuE-V2, approximately 70% of those randomized to treatment continuation and approximately 40% of those randomized to treatment withdrawal maintained facial repigmentation indicative of treatment success (i.e. ≥ F-VASI 75). Lost repigmentation could be regained in a timely manner following reinitiation of open-label active treatment.

Authors

Institutions

Publication Details

Journal
British Journal of Dermatology
Published
2025-12-24
DOI
https://doi.org/10.1093/bjd/ljaf519
Citations
1
Primary Topic
melanin and skin pigmentation
Type
article
Field-Weighted Citation Impact
1.15

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study

Deanna Kornacki, Kim Papp, Mark Amster, Jacek Zdybski et al.
1 citations
British Journal of Dermatology
melanin and skin pigmentation
1.15
article

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study

Deanna Kornacki, Kim Papp, Mark Amster, Jacek Zdybski, Maryam Shayesteh Alam, Thierry Passeron, John E. Harris, Khaled Ezzedine, Anthony A. Nuara, Shaoceng Wei, Seth Forman, Julien Sénéschal, Michael Sebastian, David Rosmarin, Amit G Pandya
article en
1 citations

Abstract

We present data from the TRuE-V1/TRuE-V2 rollover TRuE-V long-term extension study evaluating withdrawal and continuation of ruxolitinib cream treatment. Among patients with near-complete facial repigmentation in TRuE-V1/TRuE-V2, approximately 70% of those randomized to treatment continuation and approximately 40% of those randomized to treatment withdrawal maintained facial repigmentation indicative of treatment success (i.e. ≥ F-VASI 75). Lost repigmentation could be regained in a timely manner following reinitiation of open-label active treatment.

British Journal of Dermatology
Centre National de la Recherche Scientifique (FR), Inserm (FR), University of Toronto (CA), Université Paris-Est Créteil (FR), Université Côte d'Azur (FR), Centre Hospitalier Universitaire de Nice (FR), Barrie Urology Group (CA), Partners In Care (US), Hôpital Saint-André (FR), Probity Medical Research (CA), Akademii Nauk Stosowanych im. Józefa Gołuchowskiego (PL), Hôpitaux Universitaires Henri-Mondor (FR), Mahlo (Germany) (DE), Vitalant (US), Indiana University School of Medicine, Mass General Brigham (US), Indiana University – Purdue University Indianapolis (US), Incyte (United States) (US)
Incyte
Good health and well-being
Openalex Percentile: Top 17%
melanin and skin pigmentation
1.15
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.